Evidence map›Paper›PMID 24191937›Full record

ArticleCurrent HIV research2013

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Diego A Vargas-Inchaustegui, Marjorie Robert-Guroff

Abstract read
In one paragraph

Article in Current HIV research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. New prospects for a preventive HIV-1 vaccine.Journal of virus eradication · 2015
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. HIV-1 vaccines: challenges and new perspectives.Human vaccines & immunotherapeutics · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Diego A Vargas-InchausteguiVaccine Branch, Center for Cancer Research, National Cancer Institute, 41 Medlars Drive, Building 41, Room D804, Bethesda, MD 20192-5065, USA. guroffm@mail.nih.gov.
Marjorie Robert-Guroff

Funding

Development of a Vaccine for HIVAIDS: Cellular ImmunityZIABC011062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$12.8M
HUMORAL AND CELLULAR IMMUNE RESPONSES TO HUMAN AND NONHUMAN PRIMATE RETROVIRUSESZ01BC005536 · NCI · BASIC SCIENCES · PI ROBERT-GUROFF, MARJORIE · 1996 to 2007
$4.1M
Intramural NIH HHS Z01 BC005536
6 · The paper itself

Abstract

The modest success of the RV144 HIV vaccine trial in Thailand and the ensuing suggestion that a Fc-receptormediated antibody activity might have played a role in the protection observed have intensified investigations on Fcrelated immune responses. HIV neutralizing antibodies have been and continue to be the focal point of research into humoral immune protection. However, recent knowledge that their protective efficacy can be augmented by Fc-FcR interactions has increased the complexity of identifying immune correlates of protection. If anything, continued studies of both humoral and cellular immune mechanisms point to the lack of a single protective anti-HIV immune response. Here we focus on humoral immunity, analyzing the role played by Fc receptor-related responses and discussing how new knowledge of their interactions requires further investigation, but may also spur novel vaccination approaches. We initially address classical Fc-receptor mediated anti-viral mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated viral inhibition (ADCVI), and antibody-dependent cellular phagocytosis (ADCP), as well as the effector cells that mediate these functions. Next, we summarize key aspects of FcR-Fc interactions that are important for potential control of HIV/SIV such as FcR polymorphisms and post-transcriptional modifications. Finally we discuss less commonly studied non-mechanistic anti-HIV immune functions: antibody avidity and envelopespecific B cell memory. Overall, a spectrum of immune responses, reflecting the immune system's redundancy, will likely be needed to prevent HIV infection and/or disease progression. Aside from elicitation of critical immune mechanisms, a successful vaccine will need to induce mature B cell responses and long-lasting immune memory.

Indexed as

AnimalsAntibody-Dependent Cell CytotoxicityHIV AntibodiesHIV InfectionsHumansImmunoglobulin Fc FragmentsPhagocytosisPolymorphism, GeneticReceptors, IgGSimian Immunodeficiency VirusHIV AntibodiesImmunoglobulin Fc FragmentsReceptors, IgG

Identifiers

PMID24191937
PMCPMC6288814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.